ADC Cytotoxic Payload Development Platform (Microbial-Derived Payloads)

Model: ADC

Booth No: M928

Characteristic

A Strategic Partner for Fast-Tracking Precision Drug Development

Panlabs Biologics Inc. offers a specialized ADC (Antibody-Drug Conjugate) payload development platform focused on microbial-derived cytotoxic small molecules. Our product portfolio includes potent compounds such as Ansamitocin P-3 (AP3) and Calicheamicin, both sourced from specific microbial strains and known for their high cytotoxic activity in targeted therapies.

We have successfully completed strain engineering, fermentation optimization, and downstream purification for these compounds, achieving pilot-scale production at the 100-gram level or higher with high purity and scalable supply capacity. In collaboration with expert chemical synthesis partners, we also offer access to semi-synthetic derivatives such as N-Acetyl-Calicheamicin, Maytansinol (AP0), and Mertansine (DM1) to support the establishment of a comprehensive ADC payload supply chain for our clients.

In addition, we provide support in preparing CMC (Chemistry, Manufacturing, and Controls) documentation and technical transfer, accelerating the integration from R&D to commercialization. Beyond ADC payloads, Panlabs Biologics Inc. also has robust capabilities in the development and production of antibiotics, natural products, and enzymes derived from microbial sources, delivering flexible bioprocessing solutions for global clients.